The major brands in China’s urinalysis market are URIT, DIRUI, AVE, etc. URIT produced China’s first urine analyzer in 1984. And after nearly 40 years’ strenuous cultivation, it pioneered the modular urine analysis workflow using deep learning artificial intelligence (AI) image recognition technology.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Fluidigm said on Wednesday that it has completed the acquisition of InstruNor, a privately held, Oslo-based provider of integrated sample preparation systems for flow and mass cytometry.

The US International Trade Commission has upheld a judge's previous determination that certain microfluidic products imported by Bio-Rad Laboratories indirectly infringe patents held by 10x Genomics.

BioMérieux reported today that its fourth quarter revenues rose 11 percent year over year driven by sales of molecular biology reagents and microbiology instruments, as well as a strong dynamic in Asia Pacific.

Adaptive Biotechnologies reported after the close of the market on Wednesday that its fourth quarter revenues increased 41 percent year over year.

Lucid Diagnostics announced recently it has entered a research agreement with the Fred Hutchinson Cancer Research Center to evaluate the center's Barrett's Esophagus progression biomarkers using Lucid's EsoCheck Esophageal Cell Collection De

Novacyt said recently that its molecular test for the COVID-19 virus has received CE marking.

10x Genomics reported after the close of the market recently a 49 percent increase in fourth quarter revenues driven by consumables sales.

Agilent Technologies reported after the close of the market recently that its fiscal first quarter revenues rose 6 percent year over year.

Invitae reported after the close of the market recently that its fourth quarter 2019 revenues increased 47 percent from the prior year.

Diagnostics manufacturer Quidel reported after the close of the market recently that its fourth quarter revenues rose 15 percent year over year, due primarily to growth in its rapid immunoassay business.